Overview

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Status:
Recruiting

Trial end date:
2022-12-20

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers.

Phase:

Phase 1

Details

Lead Sponsor:

Mayo Clinic

Collaborators:

FDA Office of Orphan Products Development
National Cancer Institute (NCI)
Wayshine Biopharm, Inc.